TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

58 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

49 studies on the map

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — Arizona Liver Health, ChandlerA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — GSK Investigational Site, ArcadiaA Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health, ChandlerImpact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD) — Cincinnati Children's Hospital Medical Center, CincinnatiA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis — Akero Clinical Study Site, BirminghamNon-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) — National Institutes of Health Clinical Center, BethesdaA Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health - Chandler, ChandlerA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — 89bio Clinical Study Site, BirminghamImproving Coronary Vascular Health in Women — Massachusetts General Hospital, BostonHuman Models of Selective Insulin Resistance: Alpelisib, Part I — Columbia University Irving Medical Center, New YorkMechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease — Ann & Robert H Lurie Children's Hospital of Chicago, ChicagoEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Pinnacle Research Group, LLC, AnnistonA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — 89bio Clinical Study Site, BirminghamSotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford University Medical Center, StanfordA Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH — GSK Investigational Site, ChandlerThe Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD — National Institutes of Health Clinical Center, BethesdaPrevention of Progression of Prediabetes, Obesity and CV Risk — University of Texas Health Science Center at San Antonio, San AntonioEvaluating the Pharmacokinetics and Safety of Miricorilant — Site# 433, San AntonioBicalutamide Therapy in Young Women With NAFLD and PCOS — University of California San Francisco, San FranciscoEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CityMilk Thistle Clinical Trial in Pediatric NAFLD — University Hospitals Cleveland Medical Center, ClevelandA Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors — Site 108, ChandlerDigoxin In NASH (CODIN) — Yale New Haven Health, New HavenA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Akero Clinical Study Site, BirminghamMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — GSK Investigational Site, ArcadiaCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Nephrology of North Alabama, DecaturStudy to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH — University of California San Diego, La JollaA Study of Efimosfermin Alfa in Adults With Hepatic Impairment — GSK Investigational Site, RialtoEffect of Insulin Lowering on Lipogenesis — Columbia University Irving Medical Center, New YorkEffect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) — Univeristy of Colorado Anschutz Medical Campus, AuroraMetabolic Effects of Angiotensin-(1-7) — Vanderbilt University Medical Center, Nashville: Vascular Function in Health and Disease — George E Wahlen VA Medical Center, Salt Lake CityErtugliflozin in Chronic Heart Failure — Yale School of Medicine, New HavenLow-Dose Pioglitazone in Patients With NASH (AIM 2) — University of Florida, GainesvilleSympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study) — University of Kansas Medical Center, Kansas CityEstrogen Administration for the Treatment of NASH in Postmenopausal Women — Massachusetts General Hospital, BostonBehavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care — Ralph H. Johnson VA Medical Center, Charleston, SC, CharlestonPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis — University of Alabama at Birmingham, BirminghamRandomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant — Virginia Commonwealth University, RichmondA Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Arizona Liver Health, ChandlerThyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans — Harry S. Truman Memorial, Columbia, MO, ColumbiaEffect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease — Northwestern University, ChicagoEffects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults — University of Texas Health Science Center at San Antonio, San AntonioEvaluation of Miricorilant on Liver Fat in Patients With MASLD — University of Missouri, Columbia